StockData
BriaCell Therapeutics Corp. logo

BriaCell Therapeutics Corp. (BCTX) stock

BCTXNasdaqPharmaceutical PreparationsFiscal year ends July 31Also trades as BCTXL, BCTXZ
Financials through Q4 FY2026, quarter ended Jul 31, 2026Last filing: 10-K on Oct 28, 2026Score 4/30
$3.51+0.21 (+6.36%)

Close on Nov 17, 2026Market cap $30.65MP/E –Yield –

BriaCell Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

BriaCell Therapeutics's operating income for the twelve months ending Jul 31, 2026 was -$36.05M. For fiscal 2026 it was -$36.05M. The highest annual figure on record is -$3.94M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2026Jul 31, 2026-$36.05M–
FY2025Jul 31, 2025-$27.20M–
FY2024Jul 31, 2024-$33.33M–
FY2023Jul 31, 2023-$23.27M–
FY2022Jul 31, 2022-$15.29M–
FY2021Jul 31, 2021-$6.98M–
FY2020Jul 31, 2020-$3.94M–

Quarterly operating income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2026CQ2 2026Jul 31, 2026-$12.58M–
Q3 FY2026CQ1 2026Apr 30, 2026-$7.62M–
Q2 FY2026CQ4 2025Jan 31, 2026-$7.53M–
Q1 FY2026CQ3 2025Oct 31, 2025-$8.32M–
Q4 FY2025CQ2 2025Jul 31, 2025-$8.55M–
Q3 FY2025CQ1 2025Apr 30, 2025-$6.33M–
Q2 FY2025CQ4 2024Jan 31, 2025-$7.17M–
Q1 FY2025CQ3 2024Oct 31, 2024-$5.15M–
Q4 FY2024CQ2 2024Jul 31, 2024-$5.77M–
Q3 FY2024CQ1 2024Apr 30, 2024-$9.23M–
Q2 FY2024CQ4 2023Jan 31, 2024-$9.83M–
Q1 FY2024CQ3 2023Oct 31, 2023-$8.50M–
Q4 FY2023CQ2 2023Jul 31, 2023-$7.71M–
Q3 FY2023CQ1 2023Apr 30, 2023-$5.68M–
Q2 FY2023CQ4 2022Jan 31, 2023-$4.49M–
Q1 FY2023CQ3 2022Oct 31, 2022-$5.40M–
Q4 FY2022CQ2 2022Jul 31, 2022-$5.23M–
Q3 FY2022CQ1 2022Apr 30, 2022-$4.12M–
Q2 FY2022CQ4 2021Jan 31, 2022-$3.65M–
Q1 FY2022CQ3 2021Oct 31, 2021-$2.28M–
Q4 FY2021CQ2 2021Jul 31, 2021-$1.60M–
Q3 FY2021CQ1 2021Apr 30, 2021-$4.81M–
Q2 FY2021CQ4 2020Jan 31, 2021-$190.15K–

More BriaCell Therapeutics figures

See a number that looks wrong?